Alnylam Pharmaceuticals (ALNY) is a publicly traded Healthcare sector company. As of September 14, 2026, ALNY trades at $250.12 with a market cap of $33.28B and a P/E ratio of 45.23. ALNY moved +0.55% today. Year to date, ALNY is -37.46%; over the trailing twelve months it is -46.93%. Its 52-week range spans $197.81 to $495.55. Analyst consensus is strong buy with an average price target of $377.31. Rallies surfaces ALNY's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Alnylam Pharmaceuticals (ALNY) research on Rallies includes live charts, financials, analyst ratings, hedge fund holdings, politician trades, insider activity, news, AI research, and community context. ALNY moved +0.55% today. Analyst consensus is strong buy.
| Metric | Value |
|---|---|
| Price | $250.12 |
| Market Cap | $33.28B |
| P/E Ratio | 45.23 |
| EPS | $5.53 |
| Dividend Yield | 0.00% |
| 52-Week High | $495.55 |
| 52-Week Low | $197.81 |
| Volume | 938.30K |
| Avg Volume | 0 |
| Revenue (TTM) | $4.80B |
| Net Income | $733.11M |
| Gross Margin | 79.79% |
22 analysts cover ALNY: 0 strong buy, 19 buy, 3 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $377.31.